Chardan analyst Keay Nakae initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $60 price target The firm cites the potential of both the company’s late stage clinical asset for Wilson disease and its early clinical stage radiopharmaceutical development pipeline for the Buy rating. Monopar’s co-founder and Chief Executive Officer, Dr. Chandler Robinson, has a long history with the development of ALXN1840, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics, EDNOC announce EAP for MNPR-101-Zr, MNPR-101-Lu
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lucid Capital
- Monopar Therapeutics announces inclusion in Russell 3000, Russell 2000
- Monopar Therapeutics reports Q1 EPS (38c), consensus (57c)